骨髓增生异常综合征和急性髓细胞白血病患者血清转化生长因子-β1的检测  

Clinical significance of serum transforming growth factor β1 in patients with myelodysplastic syndrome or acute myelogenous leukemia

作　　者：钟明华[1] 马亮[1] 李振玲[1] 廖军鲜[1] 马一盖[1] 

机构地区：[1]中日友好医院血液科,北京100029

出　　处：《中日友好医院学报》2007年第6期330-332,344,共4页Journal of China-Japan Friendship Hospital

摘　　要：目的:探讨骨髓增生异常综合征(MDS)和急性髓细胞白血病(AML)患者血清转化生长因子-β1(TGF-β1)水平及意义。方法:采用定量双抗体夹心酶联免疫吸附试验(ELISA)检测MDS 32例、AML 21例及16例正常对照者血清中TGF-β1水平。结果:初诊AML患者与MDS患者血清TGF-β1水平均显著低于正常对照组(均P<0.01)。AML患者达完全缓解时TGF-β1水平恢复正常,未缓解和复发患者TGF-β1水平与初诊患者无显著性差异(P﹥0.05)。MDS低危型患者血清TGF-β1水平与高危型及初治AML患者相比为高,但三者间差异无统计学意义(P>0.05)。结论:检测AML和MDS患者血清TGF-β1水平变化有助于判断病情,评价疗效,估计预后。Objective：To study the significance of serum transforming growth factor β1 （TGF-β1）level in patients with myelodysplastic syndrome（MDS）and acute myelogenous leukemia（AML）.Methods：Serum TGF-β1 levels were measured by quantitative double-antibody sandwich enzyme-linked immunosorbent assay（ELISA） in 32 patients with MDS,21 with AML and 16 healthy individuals.Results：The serum levels of TGF-β1 in first visit patients with AML and MDS were significantly lower compared with normal controls （P〈0.01）.The serum TGF-β1 levels restored to normal and achieved complete remission in the AML patients.There were no difference in serum TGF-β1 between nonremission,relapse and first visit patients（P〉0.05）.The serum TGF-β1 level in low risk MDS group （RA,RAS） was higher compared with control group and high risk MDS group （RAEB,RAEB-t）but without statistically significant differences in serum TGF-β1 among the three groups（P〉 0.05）.Conelusion：The detection of serum TGF-β1 level maybe useful to judge state of illness and evaluate the curative effect and prognosis of AML and MDS.

关 键 词：转化生长因子Β1 骨髓增生异常综合征 急性髓细胞白血病 

分 类 号：R55[医药卫生—血液循环系统疾病] R733.7[医药卫生—内科学]